CoChat

Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

Open access
Naccache, Jean-Marc, Jouneau, Stéphane, Didier, Morgane, Borie, Raphaël, Cachanado, Marine, Bourdin, Arnaud, Reynaud-Gaubert, Martine, Bonniaud, Philippe, Israël-Biet, Dominique, Prévot, Grégoire, Hirschi, Sandrine, Lebargy, François, Marchand-Adam, Sylvain, Bautin, Nathalie, Traclet, Julie, Gomez, Emmanuel, Leroy, Sylvie, Gagnadoux, Frédéric, Rivière, Frédéric, Bergot, Emmanuel, Gondouin, Anne, Blanchard, Elodie, Parrot, Antoine, Blanc, François-Xavier, Chabrol, Alexandre, Dominique, Stéphane, Gibelin, Aude, Tazi, Abdellatif, Berard, Laurence, Brillet, Pierre Yves, Debray, Marie-Pierre, Rousseau, Alexandra, Kerjouan, Mallorie, Freynet, Olivia, Dombret, Marie-Christine, Gamez, Anne-Sophie, Nieves, Ana, Beltramo, Guillaume, Pastré, Jean, Le Borgne-Krams, Aurélie, Dégot, Tristan, Launois, Claire, Plantier, Laurent, Wémeau-Stervinou, Lidwine, Cadranel, Jacques, Chenivesse, Cécile, Valeyre, Dominique, Crestani, Bruno, Cottin, Vincent, Simon, Tabassome, Nunes, Hilario · 2022 · The Lancet Respiratory Medicine
Cited by 121

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND The use of cyclophosphamide in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) is unknown. Our study was designed to evaluate the efficacy and safety of four cyclophosphamide pulses in addition to high-dose methylprednisolone in this population. METHODS In this double-blind, placebo-controlled trial done in 35 departments across 31 hospitals in France, adult patients (≥18 years) with acute exacerbation of IPF and those with suspected acute exacerbation of IPF were randomly assigned in a 1:1 ratio using a web-based system to receive either intravenous pulses of cyclophosphamide (600 mg/m2) plus uromitexan as haemorrhagic cystitis prophylaxis (200 mg/m2) at the time of cyclophosphamide administration and then again, 4 h later, or placebo at days 0, 15, 30, and 60. Random assignment was stratified according to the severity of IPF and was block-balanced with variable block sizes of four or six patients. Patients receiving mechanical ventilation, with active infection, with active cancer, or who were registered on the lung transplant waiting list were excluded. All patients received standardised high-dose glucocorticoids. The investigators, patients, and the sponsor were masked to the treatment assignments. The primary endpoint was 3-month all-cause mortality, analysed by a χ2 test adhering to an intention-to-treat principle. The trial is now complete and registered with ClinicalTrials.gov, NCT02460588. FINDINGS Between Jan 22, 2016, and July 19, 2018, 183 patients were assessed for eligibility, of whom 120 patients were randomly assigned and 119 patients (62 [52%] with severe IPF) received at least one dose of cyclophosphamide (n=60) or placebo (n=59), all of whom were included in the intention-to-treat analysis. The 3-month all-cause mortality was 45% (27/60) in patients given cyclophosphamide compared with 31% (18/59) in the placebo group (difference 14·5% [95% CI -3·1 to 31·6]; p=0·10). Similar results were found after adjustment by IPF severity (odds ratio [OR] 1·89 [95% CI 0·89-4·04]). The risk of death at 3 months, independent of the treatment received, was higher with severe than non-severe IPF (OR 2·62 [1·12-6·12]) and was lower with the use of antifibrotic therapy (OR 0·33 [0·13-0·82]). Adverse events were similar between groups by 6 months (25 [42%] in the cyclophosphamide group vs 30 [51%] in the placebo group) and their proportion, including infections, did not differ. Overall infection was the main adverse event and occurred in 20 (33%) of 60 patients in the cyclophosphamide group versus 21 (36%) of 59 patients in the placebo group. INTERPRETATION In patients with acute exacerbation of IPF, adding intravenous cyclophosphamide pulses to glucocorticoids increased 3-month mortality. These findings provide evidence against the use of intravenous cyclophosphamide in such patients. FUNDING Programme Hospitalier de Recherche Clinique of the French Ministry of Health (PHRC 2014-502), Roche Pharmaceuticals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(21)00354-4

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 121

Metadata

Authors
Naccache, J.-M., Jouneau, S., Didier, M., Borie, R., Cachanado, M., Bourdin, A., Reynaud-Gaubert, M., Bonniaud, P., Israël-Biet, D., Prévot, G., Hirschi, S., Lebargy, F., Marchand-Adam, S., Bautin, N., Traclet, J., Gomez, E., Leroy, S., Gagnadoux, F., Rivière, F., Bergot, E., Gondouin, A., Blanchard, E., Parrot, A., Blanc, F.-X., Chabrol, A., Dominique, S., Gibelin, A., Tazi, A., Berard, L., Brillet, P. Y., Debray, M.-P., Rousseau, A., Kerjouan, M., Freynet, O., Dombret, M.-C., Gamez, A.-S., Nieves, A., Beltramo, G., Pastré, J., Le Borgne-Krams, A., Dégot, T., Launois, C., Plantier, L., Wémeau-Stervinou, L., Cadranel, J., Chenivesse, C., Valeyre, D., Crestani, B., Cottin, V., Simon, T., & Nunes, H.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2022-01
Volume
10
Issue
1
Pages
26-34
ISSN
2213-2600 (ISSN-L)
OpenAlex
W3196858161
Cited by
121
References
3
FWCI
11.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-2600(21)00354-4
The paper
Naccache, J.-M., Jouneau, S., Didier, M., Borie, R., Cachanado, M., Bourdin, A., Reynaud-Gaubert, M., Bonniaud, P., Israël-Biet, D., Prévot, G., Hirschi, S., Lebargy, F., Marchand-Adam, S., Bautin, N., Traclet, J., Gomez, E., Leroy, S., Gagnadoux, F., Rivière, F., . . . Nunes, H. (2022). Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(21)00354-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.